joimax® CEO & Founder talking to Global Spine Conference Chairman Jeffery Wang, MD, PhD in an 1:1 interview

Paris, France | November 2021 – During this years Global Spine Congress (GSC) joimax® CEO & Founder, Wolfgang Ries, sat down with GSC Chairman, Jeffery Wang, MD, PhD, to talk about the 20 years success of the company, education with the ESPINEA® Endoscopic Spine Academy and the future of endoscopic spine surgery!

Watch more interesting videos on our YouTube Channel!

Eurospine 2016: joimax® launches its new MultiZYTE® SI-Joint Endoscopic Therapy Set and its new Intracs® Intraoperative Navigation Tracking & Control System

Karlsruhe – October 05, 2016 – joimax®, the global acting German developer and marketer of technologies and training methods for endoscopic minimally invasive spinal surgery, will again exhibit at Eurospine 2016 taking place from October 5 – 7 in Berlin. During the conference, joimax®will launch two new products – the MultiZYTE® SI Endoscopic Sacroiliac Joint Therapy Set and its new Intracs® Intraoperative Navigation Tracking & Control System.

MultiZYTE® SI Endoscopic Sacroiliac Joint Therapy is developed for the treatment of the Sacroiliac Joint Syndrome (SIJS), which has been rediscovered as a major back pain generator in recent years. This kind of pain is commonly felt in the lower back, the gluteal region, the hip and thigh and can even radiate into the leg and foot. Until the 1930s, SI-Joint was the main reason for low back pain, but since 1934 the focus has been on disc herniation. According to recent studies 15 to 25% of all low back pain is caused by the SI-Joint and up to 43% in patients having undergone lumbosacral fusion. MultiZYTE® SI joimax® now offers a well developed and lasting treatment option for this disease.

The Intracs® Intraoperative Navigation Tracking & Control System was developed in cooperation between joimax® GmbH Karlsruhe and fiagon GmbH in Berlin, both located in Germany. With the Intracs® system, joimax® instruments can be navigated directly at the tip using Fiagons “chip at the tip” technology which allows tracking of instruments with a diameter in the 1mm range. The Intracs ® Navigation and Monitor Unit is integrated in the joimax® Endoscopic Tower and all necessary tools are tailored for the TESSYS® (transforaminal) and iLESSYS® (interlaminar) procedures as well as for minimally invasive stabilization procedures, like EndoLIF® and Percusys®. The main features of the Intracs® system are needle navigation through Vector-Tip-Target processing tools, the merging of 2D X-Rays with 3D- images of a patient’s CT or MRI scans, and the constant orientation control of any endoscope used in joimax procedures.

“With these two new developments we are in the position to enhance our endoscopic minimally-invasive product portfolio, driving adoption rates to meet new heights. With the world unique Intracs® system, navigation is now faster, safer and more accurate than ever before using an electromagnetic (EM) field. Radiation exposure for both, patients and surgeons will be significantly reduced,” says Wolfgang Ries, CEO and founder of joimax®. “Additionally the learning curve for all spinal endoscopic procedures offered by joimax® will now be significantly reduced and the rapid expansion of all these techniques is now well layed-out,” he continues.

joimax® obtains registration for all products in the Indian market

KARLSRUHE, Germany – (BUSINESS WIRE) – German-based joimax®, the market leader in technologies and training methods for full-endoscopic and minimally invasive spinal surgery, is excited to announce the full registration of all its products for India, one of the fastest growing endoscopic spine surgery markets worldwide.

The Indian registration includes all joimax® Class II and III, as well as Class I instruments, which were approved in 2023. Now, the Indian health community has access to all the latest spinal endoscopic technologies invented, developed and manufactured by joimax®.

“India is the biggest country in the world; it’s ready for emerging technology businesses like endoscopic spinal surgery,” states Santhosh Mechery, Director Spectramed Healthcare (P) Ltd. “We can’t wait to roll-out the complete joimax® portfolio in our country and enable so many patients to profit from this innovative, minimally invasive endoscopic spine surgery.”

“Earlier this year, joimax® received its CE MDR approvals, granted by TÜV-South — an important step for marketing our existing products under the new European regulation, which opened a backlog of products to India,” states joimax® Founder and CEO Wolfgang Ries. “We’re already active in more than 60 countries! These partners are eager to launch the newest joimax® treatment technologies.”

In Fall 2022, joimax®, in cooperation with Spectramed Healthcare, launched its education and training program, Endoscopic Spine Academy (ESPINEA®), in India, which has since been rolled out worldwide. ESPINEA® was founded in 2019, accredited by the Royal College of Surgeons of Edinburgh in 2020, and this year, is celebrating its 5th anniversary. The program allows for the highest quality training of joimax® products in any market, serving as a hands-on learning facility for endoscopic spinal surgery.